InvestorWire NewsRoom


Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates
September 23, 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

  • Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes
  • The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan
  • Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit
  • The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow next year

Novel pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) continues to garner attention for its development of psilocybin as potential treatments for medical conditions with largely unmet needs, presenting an overview of its business and ongoing clinical trials for its two trademarked drug candidates most recently at the Oppenheimer Fall Healthcare Summit.  

Tryp is nearing the launch of a Phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (PWS), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction.

The company also plans to execute Phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia.

Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit featured companies’ presentations and one-on-one meetings by invitation only through a virtual platform online. Tryp joined other select public companies in the sector for a presentation that paired investors with management teams to discuss key programs in detail, delivering its address on Sept. 21 (

The management team also presented an overview of the company the prior week at the H.C. Wainwright 23rd Annual Global Investment Conference and at the Canaccord Genuity Virtual Growth Conference last month. 

“I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in July ( “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.”

Tryp’s product development moves beyond the initial interests in testing psychedelics for treating solely mental health issues such as depression, anxiety, addiction, and PTSD, combining supervised administration of the drug with psychotherapy in response to select medical conditions in which specific neurological maladies play a causal role. 

Tryp also is distinguishing itself by developing a novel method of administration for its TRP-8803 candidate to make the experience better for patients, leading to a provisional patent to protect the unique features of the proprietary formulation. 

The company’s drug products are manufactured in the United States as part of an exclusive supply chain for its active ingredients that assures Tryp will have sufficient quantities to complete its clinical trials and establish eventual commercialization.

Tryp expects Phase 2a trials for the eating disorders and for phantom limb pain to begin before the end of the year (

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).